Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Novo Nordisk A/S(NVO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NVO
09/25/2026: NVO (1-star) is currently NOT-A-BUY. Pass it for now.
Novo Nordisk is a leader in the metabolic health pharmaceutical market, specifically known for its GLP-1 therapies used in diabetes and obesity treatment. The company benefits from a strong pipeline and a growing addressable market, which has fueled significant recent financial growth. Investors should be aware of risks including intense competition from companies like Eli Lilly, supply chain constraints, and potential regulatory pricing pressures. The stock is best suited for growth-oriented investors looking for exposure to chronic disease innovation, though the premium valuation warrants careful monitoring. Key developments to watch include manufacturing scaling progress and clinical trial results for expanded therapeutic indications.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is experiencing rapid revenue expansion driven by secular trends in obesity treatment. |
| Momentum investor | Strong fit while signal remains positive | The stock has shown significant upward price momentum supported by strong earnings reports. |
| Value investor | Mixed fit | The company's premium valuation reflects its growth expectations, potentially limiting the margin of safety for strict value investors. |
| Dividend investor | Mixed fit | While the dividend is reliable, the stock is currently more focused on capital appreciation than high yield. |
| Low-risk investor | Mixed fit | Pharmaceutical sector risks, including regulatory and competitive pressures, may increase volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | High investor expectations can lead to sharp price fluctuations based on clinical or supply news. |
| Valuation risk | Medium / high | A high P/E ratio requires sustained high growth to justify the current stock price. |
| Competition risk (Metabolic/GLP-1) | High | Direct rivalry with Eli Lilly in the GLP-1 market is a primary driver of future market share outcomes. |
| Business quality | Strong | The company possesses a strong competitive moat through specialized IP and integrated manufacturing. |
| Dividend income | Medium | Dividends are well-covered but secondary to the company's growth-focused capital allocation. |
| Execution risk | Medium | Successfully scaling global manufacturing capacity is critical to meeting unprecedented product demand. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -8.17% | Avg. Invested days 50 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 171.37B USD | Price to earnings Ratio 9.72 | 1Y Target Price 46.39 |
Price to earnings Ratio 9.72 | 1Y Target Price 46.39 | ||
Volume (30-day avg) 12.9M shares | Beta 0.34 | 52 Weeks Range 34.15 - 61.11 | Updated Date 09/27/2026 |
52 Weeks Range 34.15 - 61.11 | Updated Date 09/27/2026 | ||
Dividends yield (FY) 4.63% | Basic EPS (TTM) 3.99 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Diabetes Care | Insulins and GLP-1 products for diabetes management. | This is the company's foundation, providing stable cash flow from essential long-term treatments. |
| Obesity Care | GLP-1 receptor agonists (e.g., Wegovy). | This is the primary growth engine and high-margin segment currently driving most market interest. |
| Geography (North America) | Sales across the US and Canada. | North America is a critical profit center due to higher pricing power compared to other regions. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 9.72 | Forward PE 11.83 | Enterprise Value 185.16B | Price to Sales(TTM) 0.52 |
Enterprise Value 185.16B | Price to Sales(TTM) 0.52 | ||
Enterprise Value to Revenue 3.67 | Enterprise Value to EBITDA 8.18 | Shares Outstanding 3.34B | Shares Floating 3.17B |
Shares Outstanding 3.34B | Shares Floating 3.17B | ||
Percent Insiders - | Percent Institutions 9.9 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Novo Nordisk A/S
Exchange NYSE | Headquarters - | ||
IPO Launch date 1982-01-04 | President, CEO & Member of the Management Board Mr. Maziar Mike Doustdar B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 66700 | Website https://www.novonordisk.com |
Full time employees 66700 | Website https://www.novonordisk.com | ||
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.